Bone Marrow Microenvironment Remodeling in Hematologic Disorders

Abstract

The bone marrow microenvironment (BMM) is a dynamic and complex niche critical for hematopoietic stem cell (HSC) maintenance and hematopoiesis. Remodeling of the BMM is increasingly recognized as a central feature in the pathogenesis of hematologic disorders such as leukemia, myelodysplastic syndromes (MDS), and multiple myeloma. Disruption of the cellular and molecular crosstalk within this microenvironment not only drives disease initiation and progression but also impacts therapeutic response and disease relapse. Recent advances in our understanding of BMM remodeling offer new avenues for targeted therapies and refined clinical management. This review provides a comprehensive, evidence-based overview of the mechanisms, clinical implications, and therapeutic perspectives associated with bone marrow microenvironment remodeling in hematologic disorders.

Introduction

The bone marrow serves as the principal site of adult hematopoiesis, orchestrated through intricate interactions between hematopoietic and stromal cells, extracellular matrix components, and soluble mediators. The concept of the BMM as an active participant in both normal and malignant hematopoiesis has gained substantial traction, particularly over the past decade. In hematologic malignancies and disorders, aberrant remodeling of the BMM establishes a permissive milieu for clonal evolution, immune evasion, and resistance to therapy. Understanding the bidirectional interactions between hematopoietic cells and their microenvironment is thus pivotal in unraveling disease mechanisms and advancing clinical care.

Epidemiology / Disease Burden

Hematologic disorders characterized by BMM remodeling, including acute and chronic leukemias, MDS, and plasma cell dyscrasias, collectively affect millions worldwide. The global incidence of hematologic malignancies continues to rise with aging populations and improved diagnostic capabilities. For instance, multiple myeloma and MDS are more prevalent in older adults, while leukemias account for a significant proportion of childhood and adult malignancies. The burden of disease is amplified by high rates of relapse, refractory disease, and treatment-related morbidity, much of which is increasingly attributed to microenvironmental influences.

Pathophysiology

The pathophysiology of BMM remodeling involves a complex interplay between malignant and non-malignant cells. Key components include mesenchymal stromal cells, osteoblasts, endothelial cells, immune cells, and the extracellular matrix. In hematologic malignancies, malignant clones actively modify the BMM to create a niche that favors their survival and proliferation. This is achieved through secretion of cytokines, chemokines (e.g., CXCL12), growth factors, and extracellular vesicles that disrupt normal hematopoietic support. Adipocyte expansion, abnormal angiogenesis, and fibrotic changes further compromise the integrity and function of the BMM. Notably, reciprocal signaling between malignant cells and stromal components establishes a feedback loop that drives disease progression and therapeutic resistance.

Risk Factors

Genetic predispositions, chronic inflammation, exposure to cytotoxic agents, and prior bone marrow injury are established risk factors for BMM remodeling. Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized as a precursor state, conferring heightened risk for transformation to overt hematologic malignancy. Environmental factors such as radiation, toxins, and chemotherapeutic exposure can induce long-lasting alterations in the BMM, promoting dysregulated hematopoiesis and malignant transformation. Age-related changes in the stromal compartment further predispose individuals to microenvironmental dysfunction.

Clinical Features

Clinical manifestations of BMM remodeling are often indistinguishable from primary hematologic disease presentation. Patients may exhibit cytopenias, bone pain, fatigue, recurrent infections, and increased bleeding tendency. Infiltration of the BMM by malignant cells can lead to progressive marrow failure, osteolytic lesions (in myeloma), and extramedullary hematopoiesis. Importantly, BMM remodeling can also underlie resistance to standard therapies, relapse after remission, and increased risk of disease progression, underscoring its clinical relevance.

Diagnosis

Diagnosis of BMM remodeling relies on a combination of clinical, histopathological, and molecular approaches. Bone marrow biopsy remains the gold standard, providing insights into cellularity, stromal composition, fibrosis, and architectural distortion. Immunohistochemistry, flow cytometry, and advanced imaging modalities (e.g., MRI, PET-CT) further elucidate the extent and nature of microenvironmental changes. Recent advances in single-cell RNA sequencing and spatial transcriptomics have enabled high-resolution profiling of the BMM, facilitating identification of disease-specific alterations and potential therapeutic targets.

Treatment & Management

Therapeutic strategies targeting BMM remodeling are increasingly incorporated into the management of hematologic disorders. Conventional treatments such as chemotherapy, targeted agents, and hematopoietic stem cell transplantation have variable impact on the BMM. Agents that disrupt malignant cell-stroma interactions, such as CXCR4 antagonists (plerixafor), immunomodulatory drugs (lenalidomide), and monoclonal antibodies (daratumumab), show promise in reversing microenvironmental protection and enhancing therapeutic efficacy. Supportive measures, including management of bone health and mitigation of fibrosis, are integral to comprehensive care.

Recent Advances / Emerging Therapies

Recent years have witnessed considerable progress in the development of therapies specifically targeting the BMM. Small molecule inhibitors of the CXCL12/CXCR4 axis, hypoxia-activated prodrugs, and agents modulating the immune microenvironment (e.g., checkpoint inhibitors) have entered clinical trials with encouraging results. Chimeric antigen receptor (CAR) T-cell therapies are being refined to overcome microenvironmental immunosuppression. Additionally, strategies aimed at restoring normal stromal function, such as niche-targeted gene therapy and extracellular matrix modulation, represent promising avenues for future intervention.

Guideline Recommendations

Current clinical guidelines emphasize a multidisciplinary approach to diagnosis and management of hematologic disorders, incorporating assessment of BMM involvement. The National Comprehensive Cancer Network (NCCN) and European Hematology Association advocate for integration of microenvironmental biomarkers in risk stratification and therapeutic decision-making, especially in relapsed or refractory disease. Ongoing clinical trials are expected to inform future guideline updates, particularly regarding the use of BMM-targeted therapies in combination regimens.

Conclusion

Remodeling of the bone marrow microenvironment is a hallmark of hematologic disorders, with significant implications for disease pathogenesis, progression, and therapeutic response. Advances in basic and translational research have elucidated key mechanisms underlying BMM dysfunction and identified novel therapeutic targets. Integrating microenvironmental assessment into clinical practice holds promise for improving patient outcomes and guiding personalized therapy in hematologic disorders.